HOXA9 and MEIS1 have essential oncogenic roles in mixed lineage leukaemia ( MLL )-rearranged leukaemia. Here we show that they are direct targets of miRNA-196b, a microRNA (miRNA) located adjacent to and co-expressed with HOXA9 , in MLL -rearranged leukaemic cells. Forced expression of miR-196b signifi cantly delays MLL -fusion-mediated leukemogenesis in primary bone marrow transplantation through suppressing Hoxa9 / Meis1 expression. However, ectopic expression of miR-196b results in more aggressive leukaemic phenotypes and causes much faster leukemogenesis in secondary transplantation than MLL fusion alone, likely through the further repression of Fas expression, a proapoptotic gene downregulated in MLL -rearranged leukaemia. Overexpression of FAS signifi cantly inhibits leukemogenesis and reverses miR-196b-mediated phenotypes. Targeting Hoxa9 / Meis1 and Fas by miR-196b is probably also important for normal haematopoiesis. Thus, our results uncover a previously unappreciated miRNAregulation mechanism by which a single miRNA may target both oncogenes and tumour suppressors, simultaneously, or, sequentially, in tumourigenesis and normal development per cell differentiation, indicating that miRNA regulation is much more complex than previously thought.
H uman mixed lineage leukaemia ( MLL , HRX and ALL-1 ) gene, located at chromosome band 11q23, is involved in chromosomal translocations with over 60 diff erent partner genes (for example, AF4 , AF6 , AF9 , AF10 , ELL and ENL ) in ~ 10 % of acute (myeloid or lymphoid) leukaemias, which are associated with unfavourable survival 1, 2 . Th e resulting MLL fusion proteins transform cells primarily through direct upregulation of A-cluster HOX genes and HOX cofactors such as MEIS1 3 -9 . Th e mammalian HOX genes encode DNA-binding homeobox proteins that have a critical role in embryogenesis and haematopoiesis. MEIS1 is a homeodomain protein that acts as a DNA-binding cofactor of HOX proteins. HOXA and MEIS1 genes are normally expressed in haematopoietic progenitor cells and downregulated during diff erentiation 10 -12 . Aberrant overexpression of HOXA and MEIS1 genes is a hallmark of MLL -rearranged leukaemia 3, 13, 14 . HOXA9 and MEIS1 have been shown to be the most critical downstream targets of MLL fusion proteins, and their coexpression is suffi cient to transform cells and induce acute myeloid leukaemia (AML) 3 -5,15 -17 . Th eir aberrant overexpression has been shown to be required for the induction and maintenance of MLL -rearranged leukaemia 5 -9 .
MicroRNAs (miRNAs) are a class of small regulatory RNAs that bind directly to complementary sequences (usually at 3 ′ -untranslated regions; that is, 3 ′ UTRs) on target messenger RNA (mRNA) transcripts, resulting in translational repression and / or target mRNA degradation 18 -21 . Evidence is emerging that some miRNAs might have essential roles in haematopoiesis and leukemogenesis 22, 23 . We reported previously that miR-196b, a miRNA located adjacent to HOXA9 , was also aberrantly overexpressed in MLL -rearranged AML, and its knockdown by antagomir abrogated MLL -fusion-mediated cell immortalization 24 . In addition, Grimes and colleagues 25 reported recently that antagomir-mediated inhibition of miR-196b function dramatically delayed MLL-AF9 -mediated leukemogenesis in vivo . Th us, miR-196b likely functions as an oncogene and appears to be required for MLL -fusion-mediated cell transformation and leukemogenesis.
Surprisingly, both HOXA9 and MEIS1 are predicted targets of miR-196b, although they are co-expressed in MLL -rearranged leukaemia. As they all likely function as oncogenes, one may expect that there is some mechanism(s) leading to the loss of repression of miR-196b on HOXA9 / MEIS1 expression in leukaemia cells, but we found that this is not the case. In this study, we observed that forced expression of miR-196b signifi cantly inhibited MLL -fusionmediated leukemogenesis in primary mouse bone marrow transplantation (BMT), but resulted in much more aggressive leukaemic phenotypes and a faster leukemogenesis in secondary BMT recipient mice. We then showed that miR-196b could repress expression of both oncogenic (for example, HOXA9 / MEIS1 ) and tumour-suppressor (for example, FAS ) target genes, indicating that miR-196b has a dual role in MLL -fusion-mediated leukemogensis.
Results miR-196b is co-expressed with HOXA / MEIS1 in MLL leukaemia . We previously showed that miR-196b was signifi cantly overexpressed in MLL -associated AML ( Supplementary Fig. S1a ) in a bead-based miRNA profi ling of 57 samples 24, 26 , which was confi rmed in our subsequent Exiqon miRNA array assay of an independent set of 85 (70 untreated and 15 relapsed; Supplementary Table S1 ) AML and 15 normal control samples ( Supplementary Fig. S1b ). We also performed Agilent Custom Gene Array assay ( Agilent Technologies Inc. , Santa Clara, CA, USA) of 56 untreated AML and 9 normal bone marrow (BM) samples from above samples. Th rough correlating miRNA and mRNA expression profi les of the 65 samples, we found that miR-196b exhibited a signifi cantly positive correlation of expression with a group of HOXA genes and MEIS1 , and all of them were highly expressed in MLL -associated AML ( Fig. 1a ) . Th e strong co-expression between miR-196b and HOXA genes has also been observed in acute lymphoblastic leukaemia (ALL) 27 . In contrast, other HOX genes and MEIS3 were not coexpressed with miR-196b in MLL -associated AML ( Supplementary Fig. S1c ). As the human miR-196b is located at chromosome band 7p15.2, between the loci of HOXA9 and HOXA10 ( Fig. 1a ) , their co-expression suggests that they might be co-regulated.
Evidence is emerging that MLL fusion proteins bind directly to the loci of HOXA and MEIS1 genes, and enhance their expression directly through recruiting RNA polymerase II and DOT1L-mediated methylation of histone H3 lysine 79 (H3K79) 28 -31 . To determine whether MLL fusions also bind directly to the upstream region of miR-196b in human leukaemia cells as we had shown previously in mouse embryonic fi broblast cells 24 , we performed a chromatin immunoprecipitation assay, followed by quantitative PCR (qPCR) assay (see qPCR region location in Fig. 1a ). As expected, we observed a signifi cant enrichment of MLL fusion proteins, methylated H3K79 and RNA polymerase II in the upstream region of miR-196b ( Fig. 1b ) , which was associated with a higher expression level of the genes in MLL -rearranged leukaemia cells including THP1 / t(9;11) and MONOMAC6 / t(9;11), than that in non-MLLrearranged leukaemia cells such as KASUMI-1 / t(8;21) ( Fig. 1b ) .
Furthermore, we showed that forced expression of MLL-AF9 could signifi cantly ( P < 0.05; two-tailed t -test) increase the expression of miR-196b, HOXA9 / Hoxa9 and MEIS1 / Meis1 in both human umbilical cord blood CD34 + stem cells ( Fig. 1c ) and mouse haematopoietic progenitor cells ( Fig. 1d ) , confi rming their direct upregulation by MLL fusions.
miR-196b represses expression of HOXA9 and MEIS1 . Interestingly, both HOXA9 and MEIS1 are putative targets of miR-196b ( Fig. 2a ) , which was confi rmed by our luciferase reporter and mutagenesis assays in Hela ( Fig. 2b ) or 293T cells. Western blot analysis revealed that HOXA9 and MEIS1 protein levels were signifi cantly reduced by forced expression of miR-196b, and increased through inhibition of miR-196b in Hela cells ( Fig. 2b ) . However, due to their essential oncogenic roles 3,5 -8,11,32 , it might be possible that HOXA9 and MEIS1 are not repressed by miR-196b in MLL -rearranged leukaemia. To test this hypothesis, we fi rst sequenced 15 MLL -rearranged leukaemia patient samples along with fi ve human normal BM control samples, but did not fi nd any mutations or single-nucleotide polymorphisms in either the precursor of miR-196b or the genomic DNA or mRNA of the 3 ′ UTRs of HOXA9 and MEIS1 that would disrupt the repression.
Second, it was reported that under stress (for example, oxidative stress, nutrient deprivation or DNA damage), some miRNAs may switch from a normal repressor into an activator of their targets 33, 34 . To determine whether the potential oncogenic stress mediated by MLL fusions could cause such a switch in the regulatory mode of miR-196b, we performed luciferase reporter assays in Hela or 293T cells at 24, 48 or 96 h post transfection of MLL-AF9 , but did not observe such a switch. In a leukaemia cell line, MONOMAC6 bearing t(9;11), the repression of HOXA9 and MEIS1 by miR-196b was still present, as shown by luciferase reporter assays and western blot ( Fig. 2c ) . Th us, our data suggest that under potential oncogenic stress, miR-196b still represses the expression of target genes.
Finally, recent studies suggest that the loss of miRNA complementary sites through truncation of 3 ′ UTRs by alternative cleavage and polyadenylation might be a common mechanism of oncogene activation 35 -37 . Indeed, we found that the 3 ′ UTRs of both HOXA9 and MEIS1 contain multiple putative alternative polyadenylation sites ( Fig. 2d ) . Th is intrigued us to investigate whether there is a truncated 3 ′ UTR in HOXA9 and MEIS1 that prevents miR-196b-mediated repression in MLL-rearranged leukaemia. However, our Aff ymetrix Human Exon 1.0 ST array analysis of 15 MLL -rearranged AML and 9 normal control samples showed that there were no signifi cant truncations of the 3 ′ UTR of HOXA9 or MEIS1 in miR-196b overexpression delays leukemogenesis in primary BMT . As forced expression of miR-196b can signifi cantly repress the expression of HOXA9 and MEIS1 , we further assessed its function in leukemogenesis. We co-transduced MSCV-PIG (bearing a PGKpuromycin-IRES-GFP cassette) or MSCV-PIG-miR-196b together with MSCVneo, MSCVneo-MLL-AF9 or MSCVneo-MLL-ELL into the mouse foetal liver cells (E14.5; C57BL / 6) and then transplanted the cells into lethally irradiated C57BL / 6 recipient mice. We found that forced expression of miR-196b signifi cantly delayed leukemogenesis mediated by MLL-AF9 (median overall survival (OS), 62 days versus 54 days; P < 0.002; log-rank test) or MLL-ELL (median OS, 179 days versus 138 days; P < 0.0001; log-rank test) ( Supplementary Fig. S2 ).
Th e above transplanted cells were unpurifi ed and thus very heterogeneous. To validate the above results, we co-transduced 
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To reveal the mechanism underlying the longer latency caused by miR-196b, we analysed engraft ment history of the mice. Strikingly, we found that the proportion of GFP + cells in peripheral blood (PB) of miR-196b + MLL-AF9 mice 4 weeks post transplantation is 2.7 % on average, dramatically ( ~ 18-fold; P < 0.01, two-tailed t -test) lower than that (48.1 % ) of MLL-AF9 mice ( Fig. 3c ) , indicating that forced expression of miR-196b signifi cantly inhibited engraft ment. Aft er adjusting for the level of engraft ment, we found that the expression level of miR-196b in PB of miR-196b + MLL-AF9 mice is dramatically ( > 32-fold; P < 0.01, two-tailed t -test) higher at 4 weeks post transplantation whereas it is only slightly (1.4-fold) higher at the terminal stage (that is, at the time to be killed with fully developed leukaemia) than that of MLL-AF9 mice ( Fig. 3d ) . Th e relative decrease of miR-196b expression in miR-196b + MLL-AF9 mice from the 4-week stage to the terminal stage is likely due to the gradual transcriptional silencing of retroviral vectors (for example, MSCV) in haematopoietic stem cells as reported previously 38, 39 . Accordingly, the mRNA expression level of Hoxa9 and Meis1 in PB of miR-196b + MLL-AF9 mice was signifi cantly (20 -100-fold; P < 0.01, two-tailed t -test) lower in the beginning but only slightly lower at the terminal stage than that of MLL-AF9 mice ( Fig.  3d ) . Th e relative RNA expression levels of miR-196b, Hoxa9 and Meis1 in BM cells at the terminal stage showed the same pattern as those in PB ( Fig. 3e ). Interestingly, the higher level of miR-196b expression in the initial stage is largely associated with the longer latency. Th erefore, the dramatically higher expression level of miR196b in the initial stage dramatically inhibited expression of Hoxa9 and Meis1 , which leads to a much lower engraft ment and thereby a signifi cantly longer latency.
Th e miR-196b + MLL-AF9 -induced leukaemia is more aggressive . Based on the above data, one might expect that miR-196b is a tumour-suppressor gene in leukemogenesis, which, however, is contradictory to the previous fi ndings that miR-196b functions as an oncogene and is required for the MLL -fusion-mediated cell transformation and leukemogenesis 24, 25 . Indeed, consistent with the oncogenic role of miR-196b, we found that miR-196b + MLL-AF9 leukaemia cells had a higher proportion of immature blast cells than MLL-AF9 leukaemic cells in both PB and BM, and leukaemia cell infi ltration and disruption of organ architecture in liver and spleen seemed to be more aggressive in miR-196b + MLL-AF9 mice than in MLL-AF9 mice ( Fig. 4a ) . Colony-forming assay analysis showed that leukaemic BM cells from miR-196b + MLL-AF9 mice formed 6-fold more colonies than those from MLL-AF9 mice ( Fig. 4b ) , implying that the proportion of leukaemia stem / initiating cells in BM is much higher in miR-196b + MLL-AF9 than that in MLL-AF9 mice. We then transplanted BM cells isolated from two each of the control, miR-196b + MLL -AF9 , and MLL-AF9 mice, respectively, into sublethally irradiated secondary recipient mice (B6.SJL). Consistent with their more aggressive properties already shown ( Fig. 4a,b ) , miR-196b + MLL-AF9 leukaemic cells developed AML in secondary recipient mice signifi cantly faster than MLL-AF9 leukaemic cells (median OS, 19 days versus 42 days; P < 0.000004, log-rank test; Fig.  4c ). Both groups had comparable immature cells in PB and BM, but the disruption of structure in spleen and liver seemed to be more severe in miR-196b + MLL-AF9 mice than that in MLL-AF9 mice ( Fig. 4d ) . Th ese fi ndings suggest that miR-196b does have an oncogenic role in MLL -rearranged leukaemia.
Overexpression of miR-196b is associated with adverse survival . We then assessed the prognostic impact of miR-196b expression in AML patients. Th rough Cox regression analyses of the AML patients included in the bead-based miRNA profi ling 26 ( n = 28), Exiqon miRNA array (de novo AML, n = 70; relapsed AML, n = 15; Supplementary Fig. S1 ) and qPCR assay 40 ( n = 53), we found that increased expression of miR-196b was signifi cantly ( P < 0.05, Cox regression) associated with shorter OS of AML patients ( Supplementary Table S3 ). Kaplan -Meier curve analyses showed that the patients with a higher level of miR-196b expression exhibited a signifi cantly ( P < 0.05, log-rank test) shorter survival than those with a lower level in all patient sets ( Fig. 4e ) . Th rough multivariable testing in the largest patient set ( n = 70), we found that miR-196b expression signature was an independent predictor of outcome in AML aft er adjusting for other variables ( Supplementary Table S4 ).
miR-196b also targets tumour-suppressor genes such as Fas . Th e above results suggest that miR-196b must also target some critical tumour-suppressor genes, which contributes to the more aggressive leukaemic phenotypes. To identify such targets, we conducted Aff ymetrix gene arrays of leukaemic BM samples from 24 mice including 9 primary (including 3 each of negative control, MLL-AF9 and miR-196b + MLL-AF9 ) and 15 secondary (including 3 negative control, 6 MLL-AF9 and 6 miR-196b + MLL-AF9 ) recipient mice. Th rough signifi cance analysis of microarrays 41 , we identifi ed 897 genes that were signifi cantly downregulated ( q < 0.05) in all the 18 leukaemia samples relative to the 6 negative controls, and 116 were expressed at a further signifi cantly ( q < 0.05) lower level in miR-196b + MLL-AF9 than in MLL-AF9 leukaemic cells. Of the 116 genes, 41 genes are predicted as putative targets of miR-196b ( Fig. 5a ) . We then performed Aff ymetrix exon array assay of 15 human MLL -rearranged samples and 9 human normal (including 3 each of CD34 + , CD33 + and mononuclear cells) BM samples, and found that 17 out of the 41 candidates were signifi cantly ( q < 0.05; signifi cance analysis of microarrays) downregulated in MLL -rearranged leukaemia relative to normal CD33 + and mononuclear cell samples ( Fig. 5b ) . Furthermore, in a set of 485 AML patients (namely Netherlands-AML-Set; Supplementary Table S1 ) 42 , we found that among the above 17 candidate targets, only the downregulation of FAS was signifi cantly ( P < 0.05; Cox regression) associated with shorter OS and event-free survival ( Supplementary Tables S5  and S6 ; Fig. 5c ), in accordance with the association between upregulation of miR-196b and poor survival ( Fig. 4e ; Supplementary  Tables S3 and S4 ) . Th e association of downregulation of FAS with poor outcome was also observed in previous small-scale (patient number < 40) studies 43 -46 . In multivariable testing, the downregulation of FAS expression was shown as an independent predictor of poor survival aft er adjusting for other variables ( Supplementary Table S7 ). Meanwhile, F AS is a putative target of miR-196b as predicted by all the four programmes ( Fig. 5 ) . Th erefore, we chose FAS as an important tumour-suppressor candidate target of miR196b for further studies. Th e downregulation of FAS in human MLL -rearranged leukaemic cells was further confi rmed by qPCR ( Fig. 6a ) . In PB of primary BMT mice, Fas expression was signifi cantly ( P < 0.05; twotailed t -test) downregulated in both MLL-AF9 and, particularly, miR-196b + MLL-AF9 (especially at the initial stage) than in normal control samples ( Fig. 6b ) . Th rough luciferase reporter / mutagenesis assays, we showed that FAS is a direct target of miR-196b ( Fig. 6c ) . Western blot assay showed that endogenous expression of Fas was signifi cantly repressed by miR-196b in primary and secondary leukaemic BM cells ( Fig. 6d ) .
Consistent with the previous fi ndings that the downregulation of FAS is associated with decreased apoptosis 47 , we also found that ectopic expression of miR-196b signifi cantly inhibited FAS antibody-induced apoptosis in both Jurkat (35.9 % versus 15.06 % ) and MONOMAC6 (9.37 % versus 3.78 % ) cells ( Fig. 6e ) . Accordingly, immunohistochemical staining of spleen tissues with cleaved caspase-3 antibody showed that miR-196b + MLL-AF9 cells had a much lower frequency of apoptosis than MLL-AF9 cells ( Fig. 6f ) . Th ese data indicate that forced expression of miR-196b induced severe leukaemia in primary MLL -rearranged leukaemic cells and shorter latency in secondary leukaemia likely through targeting Fas .
Fas expression suppresses MLL-AF9 -mediated leukemogenesis . To validate the role of Fas in MLL -rearranged leukaemia, we forced the expression of FAS -coding region (that is, CDS, does not contain 3 ′ UTR) in both miR-196b + MLL-AF9 and MLL-AF9 primary leukaemic BM cells. We found that Fas overexpression signifi cantly delayed the development of leukaemia in secondary transplantation (median OS, 54 days versus 37 days, P < 0.05, logrank test, from miR-196b + MLL-AF9 donor cells; median OS, 83 days versus 62 days, P < 0.05, log-rank test, from MLL-AF9 donor cells) ( Fig. 7a ) . Th ere were fewer immature cells and more apoptotic cells in PB, BM, spleen and liver of FAS -overexpressing mice ( Figs 7b,c ) . Th e structure of spleen and liver was better maintained ( Fig. 7b ) , and size of spleen and liver was signifi cantly smaller ( P < 0.05; two-tailed t -test) in FAS -overexpressing mice compared with that of control mice ( Supplementary Table S8 ). Th ese results suggest that FAS expression suppresses MLL -rearranged leukaemia likely through induction of apoptosis, indicating that miR-196b repression of FAS is important in the development of MLL-fusionmediated leukemogenesis. 
miR-196b regulates

Discussion
According to our present concepts or assumptions 18, 19, 22, 23, 48 , an oncogenic miRNA would selectively repress expression of its tumour-suppressor target genes in tumourigenesis, but not aff ect expression of oncogenic potential target genes although they also have the seed sequences for the miRNA to bind; similarly, a tumoursuppressor miRNA would selectively target oncogenes but not tumour suppressors in normal development or cell diff erentiation. Th is is the logic commonly followed by most of the investigators when they are trying to identify candidate target genes of a given miRNA. However, given the fact that a single miRNA has tens or hundreds of putative target genes 49 , usually including both oncogenes and tumour suppressors, it might not be practicable for a given oncogenic or tumour-suppressor miRNA to selectively repress the expression of only the targets with opposite functions than the miRNA. By providing compelling evidence, here, we show that a poor-prognosis-related miRNA (that is, miR-196b) could repress the expression of both oncogenic (for example, HOXA9 / MEIS1 ) and tumour-suppressor (for example, FAS ) target genes simultaneously, and its repression of the critical tumour-suppressor target(s) likely has a predominant role in MLL-fusion-mediated leukemogenesis and contributes to the unfavourable prognosis of MLL -rearranged leukaemia. Notably, miR-196b is co-expressed with HOXA9 / MEIS1 in MLLrearranged leukaemia ( Fig. 1 ) , suggesting that miRNAs may also target co-expressed (that is, transcriptionally positively correlated) genes. In an analysis of over 10 individual human and mouse sample sets, we found that transcriptionally positively correlated ( P < 0.05; Pearson correlation) miRNA-putative target pairs are as frequent as, or even more frequent than, inversely (that is, negatively) correlated pairs (He C et al. , unpublished data), which is consistent with a previous study 50 , indicating that co-expression between miRNAs and putative targets is very common.
As aforementioned, we thought in the beginning that miRNAs might not negatively regulate expression of their co-expressed target genes, particularly if they have similar functions. However, although some mechanisms such as sequence mutations or single-nucleotide polymorphisms 51 , miRNA regulatory mode switch 33,34 and 3 ′ UTR truncation 35 -37 had been suggested to circumvent negative regulation of target genes by a given miRNA, none of them appears applicable in MLL -rearranged leukaemia to enable HOXA9 / MEIS1 to escape from miR-196b-mediated repression ( Fig. 2 ) . In fact, except for the few examples 33 -37 , the loss of miRNA-mediated negative regulation through these mechanisms seems rare. Th us, the negative regulation of expression of the co-expressed target genes that have similar function to the miRNA may be common.
Th e ability of a single miRNA (or a group of miRNAs) to target both oncogenes and tumour suppressors simultaneously, or sequentially, might be important for normal development and cell diff erentiation. Indeed, the potential regulation of many 3 ′ Hox (that is, Hox 1 -9) genes by miR-196 52,53 might be a highly evolutionarily conserved mechanism. In embryonic development, miR-196b may help to repress more anterior Hox programmes, and thereby reinforce the hierarchy of 5 ′ Hox function 54 . In normal haematopoiesis, miR-196b likely helps to fi ne-tune the expression of Hox genes and Meis1 in HSCs and to remove their residual transcripts in CPs to Gene  Control_P1  Control_P2  Control_P3  MA9_P1  MA9_P2  MA9_P3  miR196b-MA9_P1  miR196b-MA9_S1  miR196b-MA9_S2  miR196b-MA9_S3  miR196b-MA9_S4  miR196b-MA9_S5  miR196b-MA9_S6  miR196b-MA9_P2  miR196b-MA9_P3   Control_S1  Control_S2  Control_S3  MA9_S1  MA9_S2  MA9_S3  MA9_S4  MA9_S5  MA9_S6   4   4   3  3  3  2  2  2  2  2  2 allow further diff erentiation of the cells; when miR-196b is downregulated, Fas becomes upregulated to maintain homoeostasis of the cells (see a model in Fig. 8b ; left panel).
FAS
In human MLL -rearranged leukaemia, despite partial repression by miR-196b, HOXA9 and MEIS1 expression levels were still high enough to induce and maintain leukaemia ( Figs 1 -3,6d , and right panel of Fig. 8a ) , and therefore repression of Hoxa9 and Meis1 by miR-196b is not benefi cial but is allowable; in contrast, repression of tumour-suppressor targets (for example, Fas ; Figs 6,7 and right panel of Fig. 8a ) seems required for MLL -fusion-mediated cell transformation and leukemoegensis, and thus knockdown of miR196b expression could signifi cantly inhibit the cell transformation and leukemogensis 24, 25 . As a result, the oncogenic role of miR-196b overwhelms its tumour-suppressor role in MLL -rearranged leukaemia, and the higher level of its expression is associated with the more aggressive leukaemic phenotypes and the worse prognosis ( Fig. 4 ) .
However, in some other cases, the repression of oncogenic targets by miR-196b is more critical than its repression of tumour-suppressor targets, and as a result, the loss (or downregulation) of miR196b expression leads to the promotion of tumourigenesis, such as in ALL 55, 56 and breast cancer 57 .
Taken together, we reported here a previously unappreciated miRNA-mediated regulatory model in which a single miRNA could repress expression of both oncogenic and tumour-suppressor target genes, though the repression of one group of targets has a more dominant role than repression of the other group in determining cell fate in normal diff erentiation / development or tumourigenesis. Th is regulatory model is likely very common, given the fact that most of individual miRNAs have both oncogenic and tumour-suppressor target genes, and it is not possible for an entire group of targets to circumvent the negative regulation of a miRNA completely. In the haematopoietic system, the dynamic change of the miR-196b-mediated gene regulation in an evolutionarily conserved spatial and temporal mode is essential for normal haematopoiesis ( Fig. 8b , left panel) . However, aberrant upregulation of both miR196b and its oncogenic targets (for example, HOXA9 and MEIS1 ) by MLL fusions results in the persistent repression of expression of its tumour-suppressor targets (for example, FAS ), along with the residual high level of HOXA9 / MEIS1 , and thereby inhibits diff erentiation, disrupts cell homoeostasis and promotes cell proliferation via inhibiting apoptosis, and eventually results in cell transformation and leukemogenesis (see a model in Fig. 8b , right panel) .
It is well recognized that a single gene may function as an oncogene in some types of tissues but as a tumour suppressor in other types through a context-dependent manner (for example, Refs. 58, 59 ). Now, our data suggest that a single miRNA may target two groups of genes with distinct functions, simultaneously, or sequentially, in the same tissue / cell context, and the miRNA-mediated regulation of a dynamic balance between the two groups of target genes is essential for the normal development and cell diff erentiation; disruption of such a balance by other oncogenic events (for example, chromosomal translocation) may lead to tumourigenesis. Th us, we probably should update our present concepts about miRNA regulation in normal development / cell diff erentiation and in tumourigenesis, as well as refi ning our defi nitions of oncogenic miRNAs or tumoursuppressor miRNAs. In addition, our data also calls for cautions if we plan to target a miRNA for cancer therapy in the future. When we plan to knock down the expression of a pro-tumour miRNA by antagomiR or restore expression of an anti-tumour miRNA by mimic oligos for clinical application, we should assess the corresponding potential expression changes of some co-expressed critical targets that exhibit similar function as the miRNA (for example, knocking down miR-196b expression in MLL -rearranged leukaemia may lead to further upregulation of HOXA9 / MEIS1 ). Th us, the eff ect(s) of expression changes of those targets should be evaluated before the clinical application is pursued.
Methods
Leukaemic patient and cell line samples . All of the AML patient samples were obtained at the time of diagnosis or relapse and with informed consent at the University of Chicago Hospital (UCH) or other collaborative hospitals, and were approved by the institutional review board of the institutes / hospitals. All patients were treated according to the protocols of the corresponding institutes / hospitals. Th e clinical and molecular characteristics of these AML patients are shown in Supplementary Table S1 . Th e samples were stored in liquid nitrogen until used. Blasts and mononuclear cells were purifi ed by use of NycoPrep 1.077A ( Axis-Shield , Oslo, Norway). All cell lines were maintained in the lab.
RNA extraction and quantitative RT -PCR . Total RNA was extracted with the miRNeasy extraction kit ( Qiagen , Valencia, CA, USA) and was used as a template to synthesize complementary DNA for quantitative RT -PCR (qPCR) analysis in a 7900HT real-time PCR system ( Applied Biosystems , Foster City, CA, USA). TaqMan qPCR assay was performed to validate the diff erential expression patterns of miRNAs using kits from Applied Biosystems. qPCR with SYBR Green dye ( Qiagen ) was used to determine expression of mRNA genes. U6 RNA (for human) or snoRNA202 (for mouse) and GAPDH or PGK1 were used as endogenous controls for qPCR of miRNA and mRNA, respectively. Each sample was run in triplicate. qPCR primers are available upon request.
miRNA and mRNA expression profi ling assays . Th e miRNA expression profi ling assays of the 57 human (54 AML and 3 normal control) sample set and the 100 human (85 AML and 15 normal control) samples were conducted by use of a beadbased method 25, 28 and Exiqon miRCURY LNA arrays (v10.0; covering 757 human miRNAs; Exiqon , Woburn, MA, USA), respectively. Th e mRNA microarrays of the 65 human (56 AML and 9 normal control) sample set, the 24 human (15 MLL -rearranged AML and 9 normal control) sample set, the 24 mouse (9 primary and 15 secondary BMT) sample set and Netherlands-AML-Set ( n = 485) 42 were conducted by use of Agilent ' s custom-design microarrays ( Agilent Technologies Inc. ), Aff ymetrix GeneChip Human Exon 1.0 ST arrays , Aff ymetrix GeneChip Mouse Gene 1.0 ST arrays and Aff ymetrix U133 Plus2.0 arrays ( Aff ymetirx , Santa Clara, CA, USA), respectively. DNA extraction, amplifi cation and sequencing . Genomic DNA was extracted using DNeasy Blood & Tissue Kit ( Qiagen ) according to the manufacturer ' s instructions. Primers that cover the precursor region of miR-196b were used to amplify the genomic DNA. PCR products were purifi ed and sequenced directly. For 3 ′ UTR of HOXA9 and MEIS1 sequencing, RNA was reverse transcripted and amplifi ed with One-Step RT -PCR Kit ( Qiagen ). PCR product was purifi ed and sequenced. For primary BMT assays shown in Figure 3a , normal foetal liver cells (E14.5) of C57BL / 6 (CD45.2) mice were retrovirally transduced with MSCV-PIG + MIY (as control), MSCV-PIG-miR-196b + MIY (that is, miR-196b), MSCV-PIG + MIY-MLL-AF9 (that is, MLL-AF9 ) and MSCV-PIG-miR-196b + MIY-MLL-AF9 (that is, miR-196b + MLL-AF9 ), respectively, through two rounds of spinoculation 26 . GFP + / YFP + cells were further selected from the retrovirally transduced donor cells by fl ow cytometry, and then transplanted into lethally irradiated (960 rads) 8-to 10-week-old B6.SJL (CD45.1) recipient mice via tail vein injection, with 1 × 10 5 GFP + / YFP + cells plus a radioprotective dose of whole BM cells (1 × 10 6 ; freshly harvested from a B6.SJL mouse) per recipient mouse. Figure 4c , leukaemic or normal control BM cells isolated from the primary recipient mice were further transplanted into sublethally irradiated (480 rads) 8-to 10-week-old B6.SJL (CD45.1) secondary recipient mice via tail vein injection, with 5 × 10 5 donor cells plus a radioprotective dose of whole BM cells (1x10 6 ; freshly harvested from a B6.SJL mouse) per secondary recipient mouse.
Secondary BMT assays . For secondary BMT assays shown in
For secondary BMT assays shown in Figure 7a , leukaemic BM cells isolated from the miR-196b + MLL-AF9 or MLL-AF9 primary recipient mice were further retrovirally transduced with MSCVneo-FAS CDS (containing just the coding region of human FAS gene to avoid negative regulation of miR-196b) or MSCVneo through two rounds of spinoculation 26 . Th en, the retrovirally transduced cells were plated into 35-mm Petri dishes in 1.1 ml of Methocult M3230 methylcellulose medium ( Stem Cell Technologies Inc. , Vancouver, Canada) containing 10 ng ml − 1 each of murine recombinant IL-3, IL-6 and granulocyte-macrophage colony-stimulating factor, and 30 ng ml − 1 of murine recombinant SCF ( R & D Systems , Minneapolis, MN, USA), along with 1.0 mg ml − 1 of G418 to select transduction-positive cells. Every 2 × 10 4 retrovirally transduced cells were plated in one dish. For each transduction, there were four duplicate dishes. Cultures were incubated at 37 ° C in a humidifi ed atmosphere of 5 % CO 2 in air. Th e colony cells were collected and washed aft er 6 days of culture, and then transplanted into sublethally irradiated (480 rads) 8-to 10-week-old B6.SJL (CD45.1) secondary recipient mice via tail vein injection, with 1 × 10 6 donor cells plus a radioprotective dose of whole BM cells (1x10 6 ; freshly harvested from a B6.SJL mouse) per secondary recipient mouse.
The maintenance and end-point treatment of mice . C57BL / 6 (CD45.2) and B6. SJL (CD45.1) were purchased from the Jackson Lab (Bar Harbor, ME, USA) or Harlan Laboratories, Inc. (Indianapolis, IN, USA). Both male and female mice were used for the experiments. All laboratory mice were maintained in the animal facility at the University of Chicago. All experiments on mice in our research protocol were approved by Institutional Animal Care and Use Committee of the University of Chicago.
PB cells were collected from the transplanted recipient mice monthly via tail bleeding and at any time that the mice showed signs of systemic illness to obtain the complete blood counts with white blood cell diff erentials and the blood smears for the presence of immature or abnormal haematopoietic cells. Th e degrees of engraft ment were assessed by fl ow cytometry analysis of GFP and CD45.1 in PB. Leukaemic mice were euthanized by CO 2 inhalation if they showed signs of systemic illness, and some negative-control recipient mice were also killed at some time points (though they did not develop leukaemia) to collect specimens as conrtols for further analyses. Th e spleen, liver and thymus were weighed. Cells were obtained from the PB, BM, spleen and liver for fl ow cytometric analysis. Blood smear and BM cytospin slides were stained with Wright -Giemsa. Portions of the spleen and liver were collected for histolopathology and immunohistochemistry assays.
Histolopathology and Immunohistochemistry . Tissue samples were fi xed in formalin, embedded in paraffi n, sectioned and stained with haematoxylin and eosin. Cytospins were stained with Wright -Giemsa. In all experiments, immunostain was performed on 4 μ m thick paraffi n tissue sections of mouse spleens and livers on a Dako Autostainer ( Dako , Carpinteria, CA, USA), using a monoclonal rabbit antibody anti-cleaved caspase-3 (Asp175) (5A1E; Cell Signalling Inc. ) and rabbit EnVision-plus HRP (DAB)TM detection System ( Dako ). Briefl y, following deparaffi nization in xylene, hydration in alcohols and quenching the endogenous peroxidase in 3 % hydrogen peroxide in methanol for 5 min and antigen retrieval in Target retrieval solution ( Dako ) in a water bath at 95 ° C for 40 min, sections were incubated with anti-cleaved caspase 3 (Asp175) at dilution 1:50 overnight at 4 ° C and subsequently transferred to the Dako Autostainer where they were incubated with detection system for 30 min. Peroxidase reaction was developed using DAB provided in the detection kit. Slides were counterstained with haematoxylin, dehydrated in alcohols and mounted in mounting medium ( Sakura Finetek USA , Torrance, CA, USA).
Immunoblotting . Transiently transfected Hela, MONOMAC6 or mouse BM cells were harvested and lysed with RAPI buff er ( Pierce , Rockford, IL, USA). Proteins from the lysate were fractionated by electrophoresis through 4 -15 % polyacrylamide gels ( Bio-Rad , Hercules, CA, USA) and transferred to polyvinylidene fl uoride membranes using Tris-Glycine Transfer buff er ( Th ermo Scientifi c , BufferRockford, IL, USA). Aft er blocking with 5 % milk, membranes were incubated with various antibodies and then processed for chemiluminescent detection with ECL Plus Western Blotting Detection Reagents ( GE Healthcare , Piscataway, NJ, USA). Anti-HOXA9 or HoxA9 ( Millipore , Billerica, MA, USA), Anti-MEIS1 or Meis1 ( SDIX , Newark, DE, USA), Anti-FAS or Fas ( Santa Cruz Biotechnology Inc. , Santa Cruz, CA, USA), and anti-GAPDH ( R & D Systems ) were used for immunoblotting.
